Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
UBS
Baxter
QuintilesIMS
Daiichi Sankyo
Healthtrust
AstraZeneca
Johnson and Johnson
Mallinckrodt

Generated: November 20, 2018

DrugPatentWatch Database Preview

Entecavir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for entecavir and what is the scope of entecavir freedom to operate?

Entecavir is the generic ingredient in two branded drugs marketed by Bristol Myers Squibb, Accord Hlthcare, Amneal Pharms, Aurobindo Pharma Ltd, Breckenridge Pharm, Casi Pharms Inc, Cipla Ltd, Hetero Labs Ltd V, Par Pharm Inc, Prinston Inc, Teva Pharms Usa, and Zydus Pharms Usa Inc, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for entecavir. Eighteen suppliers are listed for this compound.

Synonyms for entecavir
1333204-94-6
142217-69-4
2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
2-amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-1H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-3H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one hydrate (1:1)
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-1H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one
2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one
209216-23-9
217E694
6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-
6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-
9-[(1S,3R,4S)-4-Hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine
AB0071164
AB1004838
ABP001043
AC-1593
AC1L4BEC
AJ-45654
AK-77289
AKOS015854916
AKOS015920226
AKOS025312554
AM20080880
AN-1116
anhydrous entecavir
Baraclude
BC677668
BMS 200475
BMS-200475
BMS-200475-01
BR-77289
BRD-K08206212-001-01-2
CAS-142217-69-4
CHEBI:473990
CHEMBL713
CS-3160
D07896
DB00442
DSSTox_CID_26446
DSSTox_GSID_46446
DSSTox_RID_81621
DTXSID4046446
E0899
entecavir (anhydrous)
Entecavir (INN)
Entecavir anhydrous
Entecavir, >=98% (HPLC)
Entecavirum
FT-0083013
GS-6386
HSDB 7334
HY-13623
J90027
KB-95857
KS-00000G4U
LS41110
MFCD00907887
MolPort-005-942-963
MolPort-006-167-546
NCGC00164563-01
NNU2O4609D
NU001508
NU006716
QDGZDCVAUDNJFG-FXQIFTODSA-N
RL01752
S-7388
SC-20106
SCHEMBL15198001
SCHEMBL28648
SQ 34,676
SQ 34676
SQ-34676
Tox21_112192
UNII-NNU2O4609D
ZINC3802690

US Patents and Regulatory Information for entecavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa ENTECAVIR entecavir TABLET;ORAL 202122-002 Aug 26, 2014 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc ENTECAVIR entecavir TABLET;ORAL 206745-002 Jun 23, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Accord Hlthcare ENTECAVIR entecavir TABLET;ORAL 205824-002 Aug 25, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva Pharms Usa ENTECAVIR entecavir TABLET;ORAL 202122-001 Aug 26, 2014 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cipla Ltd ENTECAVIR entecavir TABLET;ORAL 206872-002 Dec 6, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb BARACLUDE entecavir TABLET;ORAL 021797-002 Mar 29, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Prinston Inc ENTECAVIR entecavir TABLET;ORAL 208782-001 Oct 10, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for entecavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb BARACLUDE entecavir SOLUTION;ORAL 021798-001 Mar 29, 2005 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb BARACLUDE entecavir TABLET;ORAL 021797-002 Mar 29, 2005 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb BARACLUDE entecavir TABLET;ORAL 021797-001 Mar 29, 2005 ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb BARACLUDE entecavir SOLUTION;ORAL 021798-001 Mar 29, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
UBS
Baxter
QuintilesIMS
Daiichi Sankyo
Healthtrust
AstraZeneca
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.